These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20213205)

  • 1. Effect of incarceration history on outcomes of primary care office-based buprenorphine/naloxone.
    Wang EA; Moore BA; Sullivan LE; Fiellin DA
    J Gen Intern Med; 2010 Jul; 25(7):670-4. PubMed ID: 20213205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient satisfaction with primary care office-based buprenorphine/naloxone treatment.
    Barry DT; Moore BA; Pantalon MV; Chawarski MC; Sullivan LE; O'Connor PG; Schottenfeld RS; Fiellin DA
    J Gen Intern Med; 2007 Feb; 22(2):242-5. PubMed ID: 17356993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients.
    Moore BA; Fiellin DA; Barry DT; Sullivan LE; Chawarski MC; O'Connor PG; Schottenfeld RS
    J Gen Intern Med; 2007 Apr; 22(4):527-30. PubMed ID: 17372805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence.
    Sullivan LE; Moore BA; O'Connor PG; Barry DT; Chawarski MC; Schottenfeld RS; Fiellin DA
    Am J Addict; 2010; 19(1):53-8. PubMed ID: 20132122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public sector low threshold office-based buprenorphine treatment: outcomes at year 7.
    Bhatraju EP; Grossman E; Tofighi B; McNeely J; DiRocco D; Flannery M; Garment A; Goldfeld K; Gourevitch MN; Lee JD
    Addict Sci Clin Pract; 2017 Feb; 12(1):7. PubMed ID: 28245872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.
    Mintzer IL; Eisenberg M; Terra M; MacVane C; Himmelstein DU; Woolhandler S
    Ann Fam Med; 2007; 5(2):146-50. PubMed ID: 17389539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.
    Woody GE; Poole SA; Subramaniam G; Dugosh K; Bogenschutz M; Abbott P; Patkar A; Publicker M; McCain K; Potter JS; Forman R; Vetter V; McNicholas L; Blaine J; Lynch KG; Fudala P
    JAMA; 2008 Nov; 300(17):2003-11. PubMed ID: 18984887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial.
    Gunderson EW; Wang XQ; Fiellin DA; Bryan B; Levin FR
    Addict Behav; 2010 May; 35(5):537-40. PubMed ID: 20106601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Community-wide measures of wellness in a remote First Nations community experiencing opioid dependence: evaluating outpatient buprenorphine-naloxone substitution therapy in the context of a First Nations healing program.
    Kanate D; Folk D; Cirone S; Gordon J; Kirlew M; Veale T; Bocking N; Rea S; Kelly L
    Can Fam Physician; 2015 Feb; 61(2):160-5. PubMed ID: 25821874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.
    Fudala PJ; Bridge TP; Herbert S; Williford WO; Chiang CN; Jones K; Collins J; Raisch D; Casadonte P; Goldsmith RJ; Ling W; Malkerneker U; McNicholas L; Renner J; Stine S; Tusel D;
    N Engl J Med; 2003 Sep; 349(10):949-58. PubMed ID: 12954743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?
    Sullivan LE; Chawarski M; O'Connor PG; Schottenfeld RS; Fiellin DA
    Drug Alcohol Depend; 2005 Jul; 79(1):113-6. PubMed ID: 15943950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years.
    Fiellin DA; Moore BA; Sullivan LE; Becker WC; Pantalon MV; Chawarski MC; Barry DT; O'Connor PG; Schottenfeld RS
    Am J Addict; 2008; 17(2):116-20. PubMed ID: 18393054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence.
    Clay E; Khemiri A; Zah V; Aballéa S; Ruby J; Asche CV
    J Med Econ; 2014 Sep; 17(9):626-36. PubMed ID: 24841329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependence.
    Raisch DW; Fudala PJ; Saxon AJ; Walsh R; Casadonte P; Ling W; Johnson BA; Malkerneker U; Ordorica P; Williford WO; Sather MR
    J Am Pharm Assoc (2003); 2005; 45(1):23-32. PubMed ID: 15730114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Home buprenorphine/naloxone induction in primary care.
    Lee JD; Grossman E; DiRocco D; Gourevitch MN
    J Gen Intern Med; 2009 Feb; 24(2):226-32. PubMed ID: 19089508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid Addiction Treatment Using Buprenorphine-Naloxone In A Community-Based Internal Medicine Practice.
    Van Doren BA; Foulks-Rodriguez KA; Yarborough W
    J Okla State Med Assoc; 2015 Jul; 108(7):303-9. PubMed ID: 26390769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence.
    Bridge TP; Fudala PJ; Herbert S; Leiderman DB
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S79-85. PubMed ID: 12738352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initiation of buprenorphine during incarceration and retention in treatment upon release.
    Zaller N; McKenzie M; Friedmann PD; Green TC; McGowan S; Rich JD
    J Subst Abuse Treat; 2013 Aug; 45(2):222-6. PubMed ID: 23541303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population.
    McDermott KA; Griffin ML; Connery HS; Hilario EY; Fiellin DA; Fitzmaurice GM; Weiss RD
    J Clin Psychiatry; 2015 Feb; 76(2):189-94. PubMed ID: 25562462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Group medication management for buprenorphine/naloxone in opioid-dependent veterans.
    Berger R; Pulido C; Lacro J; Groban S; Robinson S
    J Addict Med; 2014; 8(6):415-20. PubMed ID: 25275875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.